Epilepsy Curr. 2013 Nov;13(6):297-303. doi: 10.5698/1535-7597-13.6.297.
Evidence-based guideline update: vagus nerve stimulation for the treatment of epilepsy: report of the guideline development subcommittee of the american academy of neurology.
Morris GL 3rd1, Gloss D2, Buchhalter J3, Mack KJ4, Nickels K4, Harden C5.
Author information
- 1Aurora Epilepsy Center, St. Luke's Medical Center, Milwaukee, WI.
- 2Barrow Neurologic Institute, Phoenix, AZ.
- 3University of Calgary, Alberta, Canada.
- 4Mayo Clinic, Rochester, MN.
- 5Hofstra University North Shore-Long Island Jewish Medical College, Great Neck, NY.
Abstract
OBJECTIVE:
To evaluate the evidence since the 1999 assessment regarding efficacy and safety of vagus nerve stimulation (VNS) for epilepsy, currently approved as adjunctive therapy for partial-onset seizures in patients >12 years.
METHODS:
We reviewed the literature and identified relevant published studies. We classified these studies according to the American Academy of Neurology evidence-based methodology.
RESULTS:
VNS is associated with a >50% seizure reduction in 55% (95% confidence interval [CI] 50%-59%) of 470 children with partial or generalized epilepsy (13 Class III studies). VNS is associated with a >50% seizure reduction in 55% (95% CI 46%-64%) of 113 patients with Lennox-Gastaut syndrome (LGS) (4 Class III studies). VNS is associated with an increase in ≥50% seizure frequency reduction rates of ~7% from 1 to 5 years postim-plantation (2 Class III studies). VNS is associated with a significant improvement in standard mood scales in 31 adults with epilepsy (2 Class III studies). Infection risk at the VNS implantation site in children is increased relative to that in adults (odds ratio 3.4, 95% CI 1.0-11.2). VNS is possibly effective for seizures (both partial and generalized) in children, for LGS-associated seizures, and for mood problems in adults with epilepsy. VNS may have improved efficacy over time.
RECOMMENDATIONS:
VNS may be considered for seizures in children, for LGS-associated seizures, and for improving mood in adults with epilepsy (Level C). VNS may be considered to have improved efficacy over time (Level C). Children should be carefully monitored for site infection after VNS implantation. Neurology® 2013;81:1-7.
- PMID:
- 24348133
- [PubMed] http://www.ncbi.nlm.nih.gov/pubmed/24348133
Related citations in PubMed
- Review Evidence-based guideline update: vagus nerve stimulation for the treatment of epilepsy: report of the Guideline Development Subcommittee of the American Academy of Neurology.[Neurology. 2013]
Review Evidence-based guideline update: vagus nerve stimulation for the treatment of epilepsy: report of the Guideline Development Subcommittee of the American Academy of Neurology.
Morris GL 3rd, Gloss D, Buchhalter J, Mack KJ, Nickels K, Harden C. Neurology. 2013 Oct 15; 81(16):1453-9. Epub 2013 Aug 28.
- Electrical stimulation for drug-resistant epilepsy: an evidence-based analysis.[Ont Health Technol Assess Ser. 2013]
Electrical stimulation for drug-resistant epilepsy: an evidence-based analysis.
Chambers A, Bowen J. Ont Health Technol Assess Ser. 2013 Oct 1; 13(18):1-37. Epub 2013 Oct 1.
- Vagus nerve stimulation for refractory epilepsy in children: More to VNS than seizure frequency reduction.[Epilepsia. 2009]
Vagus nerve stimulation for refractory epilepsy in children: More to VNS than seizure frequency reduction.
Shahwan A, Bailey C, Maxiner W, Harvey AS. Epilepsia. 2009 May; 50(5):1220-8. Epub 2009 Dec 15.
- Review Vagus nerve stimulation for epilepsy: a meta-analysis of efficacy and predictors of response.[J Neurosurg. 2011]
Review Vagus nerve stimulation for epilepsy: a meta-analysis of efficacy and predictors of response.
Englot DJ, Chang EF, Auguste KI. J Neurosurg. 2011 Dec; 115(6):1248-55. Epub 2011 Aug 12.
- Review Vagus nerve stimulation for partial seizures.[Cochrane Database Syst Rev. 2002]
Review Vagus nerve stimulation for partial seizures.
Privitera MD, Welty TE, Ficker DM, Welge J. Cochrane Database Syst Rev. 2002; (1):CD002896.
- [PubMed] http://www.ncbi.nlm.nih.gov/pubmed/24348133
No comments:
Post a Comment